Clinical Trial Update: Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing everolimus to sunitinib in non-clear cell renal cell carcinoma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Non-clear Cell Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Sunitinib (sunitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-04-28